2.6. Cilostazol Treatment Provides Anti-Atherosclerosis Effects in Mice with HFD-Induced Obesity and Shows Diverse Effects on PCSK9 Expression in Obese and Non-Obese Participants. This evidence concerns the gene PCSK9 and obesity disorder.